Biomarkers in Parkinson's disease (recent update)

Neurochemistry International

Volumn 63, Issue 3, 2013, Pages 201-229

  Sharma, Sushil ^a   Moon, Carolyn Seungyoun ^a   Khogali, Azza ^a   Haidous, Ali ^a   Chabenne, Anthony ^a   Ojo, Comfort ^a   Jelebinkov, Miriana ^a   Kurdi, Yousef ^a   Ebadi, Manuchair ^b  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Biomarker; Charnoly body; Diagnosis; Parkinson's disease; Synculein index

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; DJ 1 PROTEIN; FIBRINOGEN; GELATINASE B; INTERLEUKIN 1BETA; LEUCINE RICH REPEAT KINASE 2; MELATONIN; METALLOTHIONEIN; MICRORNA; N ACETYLASPARTIC ACID; NEUROFILAMENT PROTEIN; NEUROMELANIN; NEUROMODULIN; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PYRIDOXAL KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SELECTIVE ESTROGEN RECEPTOR MODULATOR; SNARE PROTEIN; TAU PROTEIN; TRANSALDOLASE; TRYPTOPHAN HYDROXYLASE 2; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; URATE;

AUTONOMIC DYSFUNCTION; AUTOPHAGY; BIOENERGY; BRAIN DEPTH STIMULATION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ELECTRON TRANSPORT; ENERGY METABOLISM; EVOKED AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HEARING IMPAIRMENT; HIGH THROUGHPUT SCREENING; HUMAN; HYPOSMIA; IMMUNOREGULATION; IMPULSIVENESS; INTRACELLULAR TRANSPORT; LETTER; LEWY BODY; LIPID METABOLISM; LIPIDOMICS; METABOLOMICS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); MUSCLE ACTION POTENTIAL; NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SUBSTANTIA NIGRA; SYNAPTOSOME;

1-METHYL, 2-PHENYL, 1, 2, 3, 6-TETRAHYDROPYRIDINE; AD; ALPHA-SYN(KO); ALS; ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANS; AUTONOMIC NERVOUS SYSTEM; BIOMARKER; CB; CHARNOLY BODY; DAT; DEMENTIA WITH LEWY BODY; DIAGNOSIS; DLB; DOPAMINE TRANSPORTER; HD; HUNTINGTON'S DISEASE; KRS; KUFOR-RAKEB SYNDROME; LBS; LEWY BODY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; METALLOTHIONEIN DOUBLE GENE KNOCKOUT; METALLOTHIONEIN TRANSGENIC; METALLOTHIONEINS; MPTP; MRI; MRS; MS; MSA; MT(DKO); MT(TRANS); MTS; MULTIPLE SCLEROSIS; MULTIPLE SYSTEM ATROPHY; PARKINSON'S DISEASE; PD; PERIPHERAL NERVOUS SYSTEM; PET; PNS; POSITRON EMISSION TOMOGRAPHY; SI; SINGLE PHOTON EMISSION TOMOGRAPHY; SPECT; SYN KNOCK OUT; Α-SYN; Α-SYNCULEIN; Α-SYNCULEIN INDEX;

BIOLOGICAL MARKERS; HUMANS; PARKINSON DISEASE;

EID: 84884883519     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2013.06.005     Document Type: Review

References (207)

1. Abdi, F., Quinn, J.F., Jankovic, J., McIntosh, M., Leverenz, J.B., Peskind, E., Nixon, R., Nutt, J., Chung, K., Zabetian, C., Samii, A., Lin, M., Hattan, S., Pan, C., Wang, Y., Jin, J., Zhu, D., Li, G.J., Liu, Y., Waichunas, D., Montine, T.J., Zhang, J., 2006. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis., 293-348. (Pubitemid 44253348)
2. Akhtar, R.S., Stern, M.B., 2012. New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications. Expert Rev. Neurother. 12, 1429- 1438.
3. Alberio, T., Fasano, M., 2011. Proteomics in Parkinson's disease: an unbiased approach towards peripheral biomarkers and new therapies. J. Biotechnol. 156, 325-337.
4. Alberio, T., Pippione, A.C., Zibetti, M., Olgiati, S., Cecconi, D., Comi, C., Lopiano, L., Fasano, M., 2012. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. Sci. Rep. 2, 953.
5. Alberio, T., Bucci, E.M., Natale, M., Bonino, D., Di Giovanni, M., Bottacchi, E., Fasano, M., 2013. Parkinson's disease plasma biomarkers: an automated literature analysis followed by experimental validation. J. Proteomics, S 1874-S-3919.
6. Al-Bunyan, M.A., 2000. Parkinson's disease. Clinical and electrophysiological evaluation. Saudi Med. J. 21 (1), 72-75.
7. Altar, C.A., Vawter, M.P., Ginsberg, S.D., 2009. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 34, 18-54.
8. Andreasen, N., Blennow, K., 2005. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. 107, 165-173.
9. Arnal, N., Cristalli, D.O., de Alaniz, M.J., Marra, C.A., 2010. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 1319, 118-130.
10. Balzer-Geldsetzer, M., Costa, A.S., Kronenburger, M., Schulz, J.B., Roske, S., Spottke, A., Wullner, U., Klockgether, T., Storch, A., Schneider, C., Riedel, O., Wittchen, H.U., Seifried, C., Hilker, R., Schmidt, N., Witt, K., Deuschl, G., Mollenhauer, B., Trenkwalder, C., Liepelt-Scarfone, I., Graber-Sultan, S., Berg, D., Gasser, T., Kalbe, E., Bodden, M., Oertel, W.H., Dodel, R., 2011. Parkinson's disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology 37, 168-176.
11. Beach, T.G., Adler, C.H., Dugger, B.N., Serrano, G., Hidalgo, J., Henry-Watson, J., Shill, H.A., Sue, L.I., Sabbagh, M.N., Akiyama, H., 2013. Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 72, 130-136.
12. Becker, G., Muller, A., Braune, S., Buttner, T., Benecke, R., Greulich, W., Klein, W., Mark, G., Rieke, J., Thumler, R., 2002. Early diagnosis of Parkinson's disease. J. Neurol. 249 (Suppl. 3), 40-48.
13. Benadiba, M., Luurtsema, G., Wichert-Ana, L., Buchpigel, C.A., Busatto Filho, G., 2012. New molecular targets for PET and SPECT imaging in neurodegenerative diseases. Rev. Bras. Psiquiatr. 34 (Suppl. 2), S125-136.
14. Benetti, F., Gustincich, S., Legname, G., 2012. Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. Expert Opin. Drug Discovery 7, 245-259.
15. Ben-Shachar, D., Bonne, O., Chisin, R., Klein, E., Lester, H., Aharon-Peretz, J., Yona, I., Freedman, N., 2007. Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: a FDG-PET study. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 807-813. (Pubitemid 46671478)
16. Beraud, D., Maguire-Zeiss, K.A., 2012. Misfolded a-Syn and toll-like receptors: therapeutic targets for Parkinson's disease. Parkinsonism Relat. Disord. 18, S17- S20.
17. Beraud, D., Hathaway, H.A., Trecki, J., Chasovskikh, S., Johnson, D.A., Johnson, J.A., Fedroff, H.J., Shimoji, M., Mhyre, T.R., Maguire-Zeiss, K.A., 2013. Microglial activation and antioxidant responses induced by the Parkinson's disease protein a-Syn. J. Neuroimmune Pharmacol. 8, 94-117.
18. Berg, D., 2006. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J. Neural Transm. Suppl. 71, 123-132. (Pubitemid 351412114)
19. Berg, D., 2008. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener. Dis. 5, 133-136. (Pubitemid 351347830)
20. Berridge, K.C., 2007. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191, 391-431. (Pubitemid 46355895)
21. Berridge, K.C., 2012. From prediction error to incentive salience: mesolimbic computation of reward motivation. Eur. J. Neurosci. 35, 1124-1143.
22. Besong-Agbo, D., Wolf, E., Jessen, F., Oechsner, M., Hametner, E., Poewe, W., Reindl, M., Oertel, W.H., Noelker, C., Bacher, M., Dodel, R., 2013. Naturally occurring a- Syn autoantibody levels are lower in patients with Parkinson disease. Neurology 80, 169-175.
23. Bidinosti, M., Shimshek, D.R., Mollenhauer, B., Marcellin, D., Schweizer, T., Lotz, G.P., Schlossmacher, M.G., Weiss, A., 2012. Novel one-step immunoassays to quantify a-Syn: applications for biomarker development and high-throughput screening. J. Biol. Chem. 287, 33691-33705.
24. Blennow, K., 2004a. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225. (Pubitemid 46589353)
25. Blum, K., Chen, A.L., Giordano, J., Borsten, J., Chen, T.J., Hauser, M., et al., 2012. The addictive brain: all roads lead to dopamine. J. Psychoactive Drugs 44, 134-143.
26. Boeve, B.F., 2010. REM sleep behavior disorder: updated review of the core features, the RBD-Neurodegenerative Disease Association, evolving concepts, controversies, and future directions. Ann. N.Y. Acad. Sci. 1184, 15-54.
27. Bogaerts, V., Theuns, J., vanBroeckhoven, C., 2008. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav. 7, 129-151. (Pubitemid 351342198)
28. Bollimuntha, S., Singh, B., Shavali, S., Sharma, S., Ebadi, M., 2005. TRPC-1-mediated inhibition of MPP+ toxicity in human SH-S-Y5Y neuroblastoma cells. J. Biol. Chem. 280, 2132-2140.
29. Bourque, M., Dluzen, D.E., Di Paolo, T., 2009. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 30, 142-157.
30. Bras, J., Verloes, A., Schneider, S.A., Mole, S.E., Guerreiro, R.J., 2012. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum. Mol. Genet. 21, 2646-2650.
31. Breen, K.C., Drutyte, G., 2013. Non-motor symptoms of Parkinson's disease: the patient's perspective. J. Neural Transm. 120, 531-535.
32. Brooks, D.J., 2007. Assessment of Parkinson's disease with imaging. Parkinsonism Relat. Disord. 13 (Suppl. 3), S268-S275. (Pubitemid 351222656)
33. Brooks, D.J., Pavese, N., 2011. Imaging biomarkers in Parkinson's disease. Prog. Neurobiol. 95, 614-628.
34. Brose, N., 2008. Altered complexin expression in psychiatric and neurological disorders: cause or consequence? Mol. Cells 25, 7-19. (Pubitemid 351611833)
35. Burn, D.J., 2006. Cortical Lewy body disease and Parkinson's disease dementia. Curr. Opin. Neurol. 19, 572-579. (Pubitemid 44760441)
36. Butterfield, D.A., Dalle-Donne, I., 2012. Redox proteomics. Antioxid. Redox Signal. 17, 1487-1489.
37. Camicioli, R.M., Hanstock, C.C., Bouchard, T.P., Gee, M., Fisher, N.J., Martin, W.R., 2007. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Mov. Disord. 22, 382-386. (Pubitemid 46569694)
38. Caranci, G., Piscopo, P., Rivabene, R., Traficante, A., Riozzi, B., Castellano, A.E., Ruggieri, S., Vanacore, N., Confaloni, A., 2013. Gender differences in Parkinson's disease: focus on plasma alpha-Syn. J. Neural Transm., 1-7.
39. Cascini, L.G., Cuccurullo, V., Restuccia, A., Tamburrini, O., Rotondo, A., Mansi, L., 2013. Neurological applications for myocardial MIBG scintigraphy. Nucl. Med. Rev. Cent. East. Eur. 16, 35-41.
40. Caudle, W.M., Bammler, T.K., Lin, Y., Pan, S., Zhang, J., 2010. Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev. Neurother. 10, 925-942.
41. Chahine, L.M., Stern, M.B., 2011. Diagnostic markers for Parkinson's disease. Curr. Opin. Neurol. 24, 309-317.
42. Chan, A.Y., Baum, L., Tang, N.L., Lau, C.Y., Ng, P.W., Hui, K.F., Mizuno, Y., Kwan, J.Y., Mok, V.C., Kuo, S.H., 2013. The role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson's disease. J. Clin. Neurosci. 20, 761-762.
43. Chen, H.M., Lin, C.Y., Wang, V., Amyloid, P., 2011. Component as a plasma marker for Parkinson's disease identified by a proteomic approach. Clin. Biochem. 44, 377- 385.
44. Cheng, H.C., Ulane, C.M., Burke, R.E., 2010. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715-725.
45. Chin, M.H., Qian, W.J., Wang, H., Petyuk, V.A., Bloom, J.S., Sforza, D.M., Laćan, G., Liu, D., Khan, A.H., Cantor, R.M., Bigelow, D.J., Melega, W.P., Camp, D.G., Smith, R.D., Smith, D.J., 2008. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J. Proteome Res. 7, 666-677. (Pubitemid 351294029)
46. Compta, Y., Santamaria, J., Ratti, L., Tolosa, E., Iranzo, A., Munoz, E., Valldeoriola, F., Casamitjana, R., Rios, J., Marti, M.J., 2009. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 132, 3308-3317.
47. Covy, J.P., Giasson, B.I., 2011. a-Syn, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Neurotoxicology 32, 622-629.
48. Crawford, P., Zimmerman, E.E., 2011. Differentiation and diagnosis of tremor. Am. Fam. Physician 83, 697-702.
49. D'Astous, M., Morissette, M., Callier, S., Di Paolo, T., 2005. Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol. J. Neurosci. Res. 80, 138-144. (Pubitemid 40577302)
50. Dehay, B., Martinez-Vicente, M., Ramirez, A., Perier, C., Klein, C., Vila, M., Bezard, E., 2012. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 8, 1389-1391.
51. Del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A.H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., Molinuevo, J.L., Parnetti, L., Perret-Liaudet, A., Saez-Valero, J., Saka, E., Urbani, A., Vanmechelen, E., Verbeek, M., Visser, P.J., Teunissen, C., 2012. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 6, 419-430.
52. Deleidi, M., Maetzler, W., 2012. Protein clearance mechanisms of alpha-Syn and amyloid-Beta in lewy body disorders. Int. J. Alzheimers Dis. 2012, 391438.
53. Devine, M.J., Gwinn, K., Singleton, A., Hardy, J., 2011. Parkinson's disease and a-Syn expression. Mov. Disord. 26, 2160-2168.
54. Duncan, G.W., Firbank, M.J., O'Brien, J.T., Burn, D.J., 2013. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease? Mov. Disord. 28, 425-438.
55. Ebadi, M., Sharma, S., 2006. Metallothioneins 1 and 2 attenuate peroxynitriteinduced oxidative stress in Parkinson's disease. Exp. Biol. Med. 231, 1576-1583. (Pubitemid 44547853)
56. Ebadi, M., Sharma, S.K., Ajjimaporn, A., Maanum, S., 2004a. Weaver mutant mouse in progression of neurodegeneration in Parkinson's disease. In: Ebadi, M., Pfeiffer, R.F. (Eds.), Parkinson's Disease. CRC Press.
57. Ebadi, M., Brown-Borg, H., Ren, J., Sharma, S., Shavali, S., El ReFaey, H., Carlson, E.C., 2006. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr. Drug Targets 7, 1-17.
58. Eller, M., Williams, D.R., 2009. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat. Rev. Neurol. 5, 561-570.
59. Federico, B., Stefano, G., Giuawppw, L., 2012. Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. Expert Opin. Drug Discovery 7, 245-259.
60. Flood, D.G., Marek, G.J., Williams, M., 2011. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem. Pharmacol. 81, 1422-1434.
61. Fonteh, A.N., Harrington, R.J., Huhmer, A.F., Biringer, R.G., Riggins, J.N., Harrington, M.G., 2006. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis. Markers 22, 39-64. (Pubitemid 41831604)
62. Fukumoto, D., Nishiyama, S., Harada, N., Yamamoto, S., Tsukada, H., 2012. Detection of ischemic neuronal damage with [18F]BMS-747158-02, a mitochondrial complex-1 positron emission tomography ligand: small animal PET study in rat brain. Synapse 66, 909-917.
63. Garibotto, V., Montandon, M.L., Viaud, C.T., Allaoua, M., Assal, F., Burkhard, P.R., Ratib, O., Zaidi, H., 2013. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin. Nucl. Med. 38, 112-127.
64. Gasser, T., Hardy, J., Mizuno, Y., 2011. Milestones in PD genetics. Mov. Disord. 26, 1042-1048.
65. Gerlach, M., Hendrich, A., Hueber, R., Jost, W., Winkler, J., Woitalla, D., Riederer, P., 2008. The early detection of Parkinson's disease: unmet needs. Neurodegener. Dis. 5, 137-139. (Pubitemid 351347831)
66. Gerlach, M., Maetzler, W., Broich, K., Hampel, H., Rems, L., Reum, T., Riederer, P., Stoffler, A., Streffer, J., Berg, D., 2012. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of diseasemodifying therapeutics. J. Neural Transm. 119, 39-52.
67. Geuze, E., Vermetten, E., Bremner, J.D., 2005. MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol. Psychiatry 10, 160- 184. (Pubitemid 40188512)
68. Giza, E., Gotzamani-Psarrakou, A., Bostantjopoulou, S., 2012. Imaging beyond the striatonigral dopaminergic system in Parkinson's disease. Hell J. Nucl. Med. 15, 224-232.
69. Goldstein, D.S., Holmes, C., Bentho, O., Sato, T., Moak, J., Sharabi, Y., Imrich, R., Conant, S., Eldadah, B.A., 2008. Biomarkers to detect central dopaminergic deficiency and distinguish from multiple system atrophy. Parkinsonism Relat. Disord. 14, 600-607.
70. Goldstein, D.S., Sewell, L., Sharabi, Y., 2011. Autonomic dysfunction in PD: a window to early detection? J. Neurol. Sci. 310, 118-122.
71. Goldstein, D.S., Holmes, C., Sharabi, Y., 2012a. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other Synopathies. Brain 135, 1900-1913.
72. Goldstein, D.S., Sullivan, P., Cooney, A., Jinsmaa, Y., Sullivan, R., Gross, D.J., Holmes, C., Kopin, I.J., Sharabi, Y., 2012b. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 123, 932- 943.
73. Goldstein, D.S., Holmes, C., Sewell, L., Park, M.Y., Sharabi, Y., 2012c. Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of Synopathy. Clin. Auton. Res. 22, 57-61.
74. Gomperts, S.N., Locascio, J.J., Rentz, D., Santarlasci, A., Marquie, M., Johnson, K.A., Growdon, J.H., 2013. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Nat. Rev. Neurol. 80, 85-91.
75. Granov, A.M., Tiutin, L.A., Stanzhevskiǐ, A.A., 2012. The application of nuclear medicine imaging in neurology, neurosurgery and psychiatry. Vestn. Ross. Akad. Med. Nauk 9, 13-18.
76. Guo, J., Sun, Z., Xiao, S., Liu, D., Jin, G., Wang, E., Zhou, J., Zhou, J., 2009. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res. 19, 1401-1403.
77. Guttman, M., Boileau, I., Warsh, J., Saint-Cyr, J.A., Ginovart, N., McCluskey, T., Houle, S., Wilson, A., Mundo, E., Rusjan, P., Meyer, J., Kish, S.J., 2007. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 14, 523-528. (Pubitemid 46587839)
78. Hall, S., Ohrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Hakan, W., Decraemer, H., Nagga, K., Minthon, L., Londos, E., Vanmechelen, E., Holmberg, B., Zetterberg, H., Blennow, K., Hansson, O., 2012. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445-1452.
79. Halperin, I., Morelli, M., Korczyn, A.D., Youdim, M.B.H., Mandel, S.A., 2009. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics 6, 128-140.
80. Hardy, J., 2010. Genetic analysis of pathways to Parkinson disease. Neuron 68, 201- 206.
81. Henchcliffe, C., Beal, M.F., 2008. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4, 600-609.
82. Herrmann, W., Obeid, R., 2007. Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid. Clin. Chem. Lab. Med. 45, 1614-1620. (Pubitemid 350232960)
83. Ho, G.J., Liang, W., Waragai, M., Sekiyama, K., Masliah, E., Hashimoto, M., 2011. Bridging molecular genetics and biomarkers in Lewy body and related disorders. Int. J. Alzheimers Dis. 2011, 1-18.
84. Hohlefeld, F.U., Huebl, J., Huchzermeyer, C., Schneider, G.H., Schonecker, T., Kuhn, A.A., Curio, G., Nikulin, V.V., 2012. Long-range temporal correlations in the subthalamic nucleus of patients with Parkinson's disease. Eur. J. Neurosci. 36, 2812-2821.
85. Houlden, H., Singleton, A.B., 2012. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124, 325-338.
86. Hwang, K.H., Kim, Y.K., 2004. Promoting effect and recovery activity from physical stress of the fruit of Morus alba. Biofactors 21, 267-271.
87. Jellinger, K.A., 2012. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 27, 8-30.
88. Jin, J., Meredith, G.E., Chen, L., Zhou, Y., Xu, J., Shie, F.S., Lockhart, P., Zhang, J., 2005. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res. Mol. Brain Res. 134, 119- 138. (Pubitemid 40403644)
89. Karen, L., Jaunarajs, E., Angoa-Perez, M., Kuhn, D.M., Bishop, C., 2011. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of L-DOPA treatment. Neurosci. Biobehav. Rev. 35, 556-564.
90. Kasuga, K., Nishizawa, M., Ikeuchi, T., 2012. a-Syn as CSF and blood biomarker of dementia with Lewy bodies. Int. J. Alzheimers Dis. 2012.
91. Katzenschlager, R., 2011. Dopaminergic dysregulation syndrome in Parkinson's disease. J. Neurol. Sci. 310, 271-275.
92. Klegeris, A., McGeer, E.G., McGeer, P.L., 2007. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 20, 351-357. (Pubitemid 46743120)
93. Klein, C., Lohmann-Hedrich, K., 2007. Impact of recent genetic findings in Parkinson's disease. Curr. Opin. Neurol. 20, 453-464. (Pubitemid 47051994)
94. Kohl, Z., Winner, B., Ubhi, K., Rockenstein, E., Mante, M., Munch, M., Barlow, C., Carter, T., Masliah, E., Winkler, J., 2012. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T Syn mouse model. Eur. J. Neurosci. 35, 10-19.
95. Koller, W.C., 1992. When does Parkinson's disease begin? Neurology 42, 27-31.
96. Kringelbach, M.L., Berridge, K.C., 2009. Towards a functional neuroanatomy of pleasure and happiness. Trends Cogn. Sci. 13, 479-487.
97. Kroksveen, A.C., Opsahl, J.A., Aye, T.T., Ulvik, R.J., Berven, F.S., 2011. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 74, 371-388.
98. Kumar, A., Singh, B.K., Ahmad, I., Shukla, S., Patel, D.K., Srivastava, G., Kumar, V., Pandey, H.P., Singh, C., 2012. Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity. Brain Res. 1438, 48-64.
99. Leentjens, A.F., Lousberg, R., Verhey, F.R., 2002. Markers for depression in Parkinson's disease. Acta Psychiatr. Scand. 106, 196-201.
100. Leonard, B.E., Myint, A., 2006. Changes in the immune system in depression and dementia: causal or coincidental effects? Dialogues Clin. Neurosci. 8, 163- 174. (Pubitemid 44113988)
101. Leverenz, J.B., Umar, I., Wang, Q., Montine, T.J., McMillan, P.J., Tsuang, D.W., Jin, J., Pan, C., Shin, J., Zhu, D., Zhang, J., 2007. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 17, 139-145. (Pubitemid 46466133)
102. Li, Y.H., Wang, J., Zheng, X.L., Zhang, Y.L., Li, X., Yu, S., He, X., Chan, P., 2011. Matrixassisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in Parkinson's disease. Eur. Neurol. 65, 105-111.
103. Li, J., Liu, D., Sun, L., Lu, Y., Zhang, Z., 2012. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci. 317, 1-5.
104. Licker, V., Kovari, E., Hochstrasser, D.F., Burkhard, P.R., 2009. Proteomics in human Parkinson's disease research. J. Proteomics 73, 10-29.
105. Liepelt-Scarfone, I., Behnke, S., Godau, J., Schweitzer, K.J., Wolf, B., Gaenslen, A., Berg, D., 2011. Relation of risk factors and putative premotor markers for Parkinson's disease. J. Neural Transm. 118, 579-585.
106. Lin, X., Cook, T.J., Zabetian, C.P., Leverenz, J.B., Peskind, E.R., Hu, S.C., Cain, K.C., Pan, C., Edgar, J.S., Goodlett, D.R., Racette, B.A., Checkoway, H., Montine, T.J., Shi, M., Zhang, J., 2012. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Curr. Neurol. Neurosci. Rep. 2, 954.
107. Linazasoro, G., Sesar, A., Valldeoriola, F., Compta, Y., Herrero, M.T., Martinez Castrillo, J.C., Lopez Lozano, J.J., Bergaretxe, A., Vela, L., Fernandez, J.M., Castro, A., Kulisevski, J., Lezcano, E., Vaamonde, J., Lopez Del Val, J., Chacon, J., Vivancos, F., Luquin, R., Aguilar, M., Burguera, J.A., Salvador, C., Menendez Guisasola, L., Catalan, M.J., Mir, P., Campos, V., Grandas, F., Minguez, A., Balaguer, E., Yanez, R., Leiva, C., Garcia Ruiz, P., Cubo, E., 2009. Neuroprotection in Parkinson's disease: analysis though group of experts' methodology. Neurologia 24, 113-124.
108. Litteljohn, D., Hayley, S., 2012. Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach. Methods Mol. Biol. 934, 121-144.
109. Liu, B., Shi, Q., Ma, S., Feng, N., Li, J., Wang, L., Wang, X., 2008. Striatal 19S Rpt6 deficit is related to alpha-Syn accumulation in MPTP-treated mice. Biochem. Biophys. Res. Commun. 376, 277-282.
110. Lopes da Fonseca, T., Correia, A., Hasselaar, W., van der Linde, H.C., Willemsen, R., Outeiro, T.F., 2013. The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival. Brain Res. Bull. 90, 118-126.
111. Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto, M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I., Ohki, M., Inazawa, J., Hirohashi, S., 2007. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 98, 392-400. (Pubitemid 46195611)
112. Lu, B., 2003. BDNF and activity-dependent synaptic modulation. Learn. Mem. 10, 86-98. (Pubitemid 36418719)
113. Luo, J., 2010. Lithium-mediated protection against ethanol neurotoxicity. Front Neurosci. 4, 41.
114. Maarouf, C.L., Beach, T.G., Adler, C.H., Malek-Ahmadi, M., Kokjohn, T.A., Dugger, B.N., Walker, D.G., Shill, H.A., Jacobson, S.A., Sabbagh, M.N., Roher, A.E., 2013. Arizona Parkinson's Disease Consortium. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights 8, 19-28.
115. Madampage, C., Tavassoly, O., Christensen, C., Kumari, M., Lee, J.S., 2012. Nanopore analysis: an emerging technique for studying the folding and misfolding of proteins. Prion 6, 116-123.
116. Maetzler, W., Liepelt, I., Berg, D., 2009. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 8, 1158-1171.
117. Marek, K., Jennings, D., Tamagnan, G., Seibyl, J., 2008. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann. Neurol. 64, S111-S121.
118. Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., Poewe, W., Mollenhauer, B., Sherer, T., Frasier, M., Meunier, C., Rudolph, A., Casaceli, C., Seibyl, J., Mendick, S., Schuff, N., Zhang, Y., Toga, A., Crawford, K., Ansbach, A., De Blasio, P., Piovella, M., Trojanowski, J., Shaw, L., Singleton, A., Hawkins, K., Eberling, J., Brooks, D., Russell, D., Leary, L., Factor, S., Sommerfeld, B., Hogarth, P., Pighetti, E., Williams, K., Standaert, D., Guthrie, S., Hauser, R., Delgado, H., Jankovic, J., Hunter, C., Stern, M., Tran, B., Leverenz, J., Baca, M., Frank, S., Thomas, C.A., Richard, I., Deeley, C., Rees, L., Sprenger, F., Lang, E., Shill, H., Obradov, S., Fernandez, H., Winters, A., Berg, D., Gauss, K., Galasko, D., Fontaine, D., Mari, Z., Gerstenhaber, M., Brooks, D., Malloy, S., Barone, P., Longo, K., Comery, T., Ravina, B., Grachev, I., Gallagher, K., Collins, M., Widnell, K.L., Ostrowizki, S., Fontoura, P., La-Roche, F., Ho, T., Luthman, J., van der Brug, M., Reith, A.D., Taylor, P., 2011. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629-635.
119. Mark, R., Cookson, I., Dauer, W., Dawson, T., Fon, E.A., Guo, M., Shen, J., 2007. The roles of kinases in familial Parkinson's disease. J. Neurosci. 27, 11865-11868. (Pubitemid 350072099)
120. Marti, M.J., Tolosa, E., 2013. Parkinson disease: new guidelines for diagnosis of Parkinson disease. Nat. Rev. Neurol. 9, 190-191.
121. Martin, H.L., Teismann, P., 2009. Glutathione - a review on its role and significance in Parkinson's disease. FASEB J. 23, 3263-3272.
122. Mellick, G.D., Silburn, P.A., Sutherland, G.T., Siebert, G.A., 2010. Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. Expert Rev. Mol. Diagn. 10, 1035-1050.
123. Melrose, H., 2008. Update on the functional biology of Lrrk2. Future Neurol. 3 (6), 669-681.
124. Mendonca, D.M., Pizzati, L., Mostacada, K., de S Martins, S.C., Higashi, R., Ayres Sa, L., Moura Neto, V., Chimelli, L., Martinez, A.M., 2012. Neuroproteomics: an insight into ALS. Neurol. Res. 34, 937-943.
125. Michell, A.W., Lewis, S.J.G., Foltynie, T., Barker, R.A., 2004. Biomarker and Parkinson's disease. Brain 127, 1693-1705.
126. Mignot, E., Lammers, G.J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., Schrader, H., Nishino, S., 2002. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553-1562.
127. Mischley, L.K., Allen, J., Bradley, R., 2012. Coenzyme Q10 deficiency in patients with Parkinson's disease. J. Neurol. Sci. 318, 72-75.
128. Mollenhauer, B., Trenkwalder, C., 2009. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov. Disord. 24 (10), 1411-1426.
129. Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel-Doring, F., Ebentheuer, J., Trenkwalder, C., Schlossmacher, M.G., 2013. Total CSF a-Syn is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48.
130. Molochnikov, L., Rabey, J.M., Dobronevsky, E., Bonucelli, U., Ceravolo, R., Frosini, D., Grunblatt, E., Riederer, P., Jacob, C., Aharon-Peretz, J., Bashenko, Y., Youdim, M.B., Mandel, S.A., 2012. A molecular signature in blood identifies early Parkinson's disease. Mol. Neurodegener. 31 (7), 26.
131. Morgan, J.C., Mehta, S.H., Sethi, K.D., 2010. Biomarkers in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 10, 423-430.
132. Morley, J.F., Weintraub, D., Mamikonyan, E., Moberg, P.J., Siderowf, A.D., Duda, J.E., 2011. Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov. Disord. 26, 2051-2057.
133. Mouradian, M.M., 2012. MicroRNAs in Parkinson's disease. Neurobiol. Dis. 46, 279- 284.
134. Noureddine, M.A., Li, Y.J., van der Walt, J.M., Walters, R., Jewett, R.M., Xu, H., Wang, T., Walter, J.W., Scott, B.L., Hulette, C., Schmechel, D., Stenger, J.E., Dietrich, F., Vance, J.M., Hauser, M.A., 2005. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov. Disord. 20 (10), 1299-1309. (Pubitemid 41645904)
135. Oei, N.Y., Rombouts, S.A., Soeter, R.P., van Gerven, J.M., Both, S., 2012. Dopamine modulates reward system activity during subconscious processing of sexual stimuli. Neuropsychopharmacology 37, 1729-1737.
136. Orru, G., Pettersson-Yeo, W., Marquand, A.F., Sartori, G., Mechelli, A., 2012. Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci. Biobehav. Rev. 36, 140-152.
137. Osterberg, N., Wiehle, M., Oehlke, O., Heidrich, S., Xu, C., Fan, C.M., Krieglstein, K., Roussa, E., 2011. Sim1 is a novel regulator in the differentiation of mouse dorsal raphe serotonergic neurons. PLoS One 6, e19239.
138. Pan, S., Rush, J., Peskind, E.R., Galasko, D., Chung, K., Quinn, J., Jankovic, J., Leverenz, J.B., Zabetian, C., Pan, C., Wang, Y., Oh, J.H., Gao, J., Zhang, J., Montine, T., Zhang, J., 2008. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res. 7 (2), 720-730. (Pubitemid 351294034)
139. Pankratz, N., Beecham, G.W., DeStefano, A.L., Dawson, T.M., Doheny, K.F., Factor, S.A., Hamza, T.H., Hung, A.Y., Hyman, B.T., Ivinson, A.J., Krainc, D., Latourelle, J.C., Clark, L.N., Marder, K., Martin, E.R., Mayeux, R., Ross, O.A., Scherzer, C.R., Simon, D.K., Tanner, C., Vance, J.M., Wszolek, Z.K., Zabetian, C.P., Myers, R.H., Payami, H., Scott, W.K., Foroud, T., 2012. PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann. Neurol. 71, 370-384.
140. Pedrosa, D.J., Timmermann, L., 2013. Review: management of Parkinson's disease. Neuropsychiatric Dis. Treat. 9, 321-340.
141. Perez-Gomez, M., Junque, C., Mercader, J.M., Berenguer, J., 2000. Application of magnetic resonance spectroscopy in the study of brain disease. Nat. Rev. Neurol. 30, 155-160. (Pubitemid 30445292)
142. Pfefferkorn, C.M., Jiang, Z., Lee, J.C., 2012. Biophysics of a-Syn membrane interactions. Biochim. Biophys. Acta 1818, 162-171.
143. Pluchino, N., Russo, M., Santoro, A.N., Litta, P., Cela, V., Genazzani, A.R., 2013. Steroids hormones and BDNF. Neuroscience 239, 271-279.
144. Poewe, W., Gauthier, S., Aarsland, D., Leverenz, J.B., Barone, P., Weintraub, D., Tolosa, E., Dubois, B., 2008. Diagnosis and management of Parkinson's disease dementia. Int. J. Clin. Pract. 62, 1581-1587.
145. Politis, M., Loane, C., Wu, K., O'Sullivan, S.S., Woodhead, Z., Kiferle, L., et al., 2013. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Curr. Opin. Neurol. 136, 400-411.
146. Postuma, R.B., Lang, A.E., Massicotte-Marquez, J., Montplaisir, J., 2006. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Nat. Rev. Neurol. 66, 845-851. (Pubitemid 43739758)
147. Postuma, R.B., Gagnon, J.F., Montplaisir, J., 2010. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J. Neurol. Neurosurg. Psychiatry 81, 1008-1013.
148. Postuma, R.B., Aarsland, D., Barone, P., Burn, D.J., Hawkes, C.H., Oertel, W., Ziemssen, T., 2012. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov. Disord. 27, 617-626.
149. Poulopoulos, M., Levy, O.A., Alcalay, R.N., 2012. The neuropathology of
150. Power, J.D., Barnes, K.A., Snyder, A.Z., Schlaggar, B.L., Petersen, S.E., 2012. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 59, 2142-2154.
151. Quinones, M.P., Kaddurah-Daouk, R., 2009. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35, 165-176.
152. Rachael, A., Dunlop, R.A., Brunk, U.T., Rodgers, K.J., 2009. Oxidized proteins: mechanisms of removal and consequences of accumulation. IUBMB Life 61, 522-527.
153. Rango, M., Arighi, A., Marotta, G., Ronchi, D., Bresolin, N., 2013. PINK1 parkinsonism and Parkinson disease: distinguishable brain mitochondrial function and metabolomics. Mitochondrion 13 (1), 59-61.
154. Ravina, B., Tanner, C., Dieuliis, D., Eberly, S., Flagg, E., Galpern, W.R., Fahn, S., Goetz, C.G., Grate, S., Kurlan, R., Lang, A.E., Marek, K., Kieburtz, K., Oakes, D., Elliott, R., Shoulson, I., 2009. Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov. Disord. 24, 2081-2090.
155. Ray, P., Le Manach, Y., Riou, B., Houle, T.T., 2010. Statistical evaluation of a biomarker. Anesthesiology 112, 1023-1040.
156. Richard, A., Armstrong, R.A., Lantos, P.L., Cairns, N.J., 2008. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathology 28, 351-365. (Pubitemid 351798982)
157. Robinson, P.A., 2010. Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy. Expert Rev. Proteomics 7 (4), 565-578.
158. Roodveldt, C., Labrador-Garrido, A., Izquierdo, G., Pozo, D., 2011. Alpha-Syn and the immune response in Parkinson's disease. In: Finkelstein, David (Ed.), Towards New Therapies for Parkinson's Disease. InTech Publishers, Shanghai, China, pp. 58-76 (Chapter 4).
159. Roongroj, B., Reichmann, H., 2013. Different diagnostic criteria for Parkinson disease: what are the pitfalls? J. Neural Transm. 120, 619-625.
160. Rossi, M., Ruottinen, H., Soimakallio, S., Elovaara, I., Dastidar, P., 2013. Clinical MRI for iron detection in Parkinson's disease. Clin. Imaging 37, 631-636.
161. Sanchez, M., Bourque, M., Morissette, M., Di Paolo, T., 2010. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, 43-71.
162. Schlossmacher, M.G., Mollenhauer, B., 2010. Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future causedirected trials. Biomark Med. 4, 647-650.
163. Schultheis, P.J., Fleming, S.M., Clippinger, A.K., Lewis, J., Tsunemi, T., Giasson, B., Dickson, D.W., Mazzulli, J.R., Bardgett, M.E., Haik, K.L., Ekhator, O., Chava, A.K., Howard, J., Gannon, M., Hoffman, E., Chen, Y., Prasad, V., Linn, S.C., Tamargo, R.J., Westbroek, W., Sidransky, E., Krainc, D., Shull, G.E., 2013. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited a-Syn accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 22, 2067-2082.
164. Shabbir, F., Patel, A., Mattison, C., Bose, S., Krishnamohan, R., Sweeney, E., Sandhu, S., Nel, W., Rais, A., Sandhu, R., Ngu, N., Sharma, S., 2013. Effect of diet on serotonergic neurotransmission in depression. Neurochem. Int. 62, 324-329.
165. Sharma, S.K., Ebadi, M., 2004. An improved method for analyzing coenzyme Q homologues and multiple detection of rare biological samples. J. Neurosci. Methods 137, 1-8. (Pubitemid 38766152)
166. Sharma, S., Ebadi, M., 2005. Distribution kinetics of 18F-DOPA in weaver mutant mice. Mol. Brain Res. 139, 23-30. (Pubitemid 41583586)
167. Sharma, S., Ebadi, M., 2008a. SPECT Neuroimaging in Translational Research of CNS Disorders. Neurochem. Int. 52, 352-362.
168. Sharma, S., Ebadi, M., 2011a. Therapeutic potential of metallothioneins as antiinflammatory agents in polysubstance abuse. J. Inst. Integr. Omics Appl. Biotechnol. (IIOAB J.) 2, 50-61.
169. Sharma, S., Ebadi, M., 2011b. Metallothioneins as early & sensitive biomarkers of redox signaling in neurodegenerative disorders. J. Inst. Integr. Omics Appl. Biotechnol. (IIOAB J.) 2, 98-106.
170. Sharma, S., Ebadi, M., 2014. Antioxidants as potential therapeutics in Parkinson's disease. In: Laher, I. (Ed.), System Biology of Oxidative Stress. Springer Verlag, Germany, pp. 1-84 (Chapter 85).
171. Sharma, S., Carlson, E., Ebadi, M., 2003. The neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in dopaminergic neurons. J. Neurocytol. 32, 329-343. (Pubitemid 38197813)
172. Sharma, S., Kheradpezhou, M., Shavali, S., El Refaey, H., Eken, J., Hagen, C., Ebadi, M., 2004. Neuroprotective actions of coenzyme Q10 in Parkinson's disease. Methods Enzymol. 382, 488-509. (Pubitemid 38240807)
173. Sharma, S., Refaey, H.El., Ebadi, M., 2006. Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull. 70, 22-32. (Pubitemid 43783378)
174. Sharma, S., Rays, A., Nel, W., Sandhu, R., Ebadi, M., 2013. Clinical significance of metallothioneins in cell therapy and nanomedicine. Int. J. Nanomed. 8, 1477- 1488.
175. Shi, M., Caudle, W.M., Zhang, J., 2009. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis. 35, 157-164.
176. Shi, M., Huber, B.R., Zhang, J., 2010. Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol. 20, 660-671.
177. Shi, M., Bradner, J., Hancock, A.M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., Jankovic, J., Zabetian, C.P., Kim, H.M., Leverenz, J.B., Montine, T.J., Ginghina, C., Kang, U.J., Cain, K.C., Wang, Y., Aasly, J., Goldstein, D., Zhang, J., 2011. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570-580.
178. Shtilbans, A., Henchcliffe, C., 2012. Biomarkers in Parkinson's disease: an update. Curr. Opin. Neurol. 25, 460-465.
179. Sierra, M., Sanchez-Juan, P., Martinez-Rodriguez, M.I., Gonzalez-Aramburu, I., Garcia-Gorostiaga, I., Quirce, M.R., Palacio, E., Carril, J.M., Berciano, J., Combarros, O., Infante, J., 2013. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 80 (7), 621-626.
180. Speigel, J., 2011. Impact of dopamine transporter scan in Parkinson's disease. In: Rana, Abdul Qayyum (Ed.), Diagnosis and Treatment of Parkinson's disease. InTech Publishers, pp. 21-28.
181. Srinivasan, V., Cardinali, D.P., Srinivasan, U.S., Kaur, C., Brown, G.M., Spence, D.W., Hardeland, R., Pandi-Perumal, S.R., 2011. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther. Adv. Neurol. Disord. 4 (5), 297-317.
182. Srivastava, G., Singh, K., Tiwari, M.N., Singh, M.P., 2010. Proteomics in Parkinson's disease: current trends, translational snags and future possibilities. Expert Rev. Proteomics 7 (1), 127-139.
183. Stefanis, L., 2012. a-Synulclein in Parkinson's disease. Cold Spring Harb. Prospect. 2 (2), 00939.
184. Surmeier, D.J., Sulzer, D., 2013. The pathology roadmap in Parkinson disease. Prion 7 (1), 85-91.
185. Tamatam, A., Khanum, F., Bawa, A.S., 2012. Genetic biomarkers of depression. Indian J. Hum. Genet. 18, 20-33.
186. Tan, S.K., Hartung, H., Sharp, T., Temel, Y., 2011. Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus? Neuropharmacology 61, 387-399.
187. Tansey, M.G., Goldberg, M.S., 2010. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518.
188. Teixeira, A.L., Barbosa, I.G., Diniz, B.S., Kummer, A., 2010. Circulating levels of brainderived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med. 4, 871-887.
189. Thomas, L. et al., 2013. Biomarkers in Alzheimer's disease and Lewy body disorders with dementia. Int. J. Alzheimer's Dis. 2013. Article ID 473181, 2 p.
190. Usenovic, M., Tresse, E., Mazzulli, J.R., Taylor, J.P., Krainc, D., 2012. Deficiency of ATP13A2 leads to lysosomal dysfunction, a-Syn accumulation, and neurotoxicity. J. Neurosci. 32, 4240-4246.
191. Ushe, M., Perlmutter, Joel S., 2013. Sex, drugs and Parkinson's disease. Brain 136, 371-373.
192. van Dijk, K.D., Teunissen, C.E., Drukarch, B., Jimenez, C.R., Groenewegen, H.J., Berendse, H.W., van de Berg, W.D., 2010. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol. Dis. 39, 229-241.
193. Varcin, M., Bentea, E., Michotte, T., Sarre, S., 2012. Oxidative stress in genetic mouse models of Parkinson's disease. Oxid. Med. Cell Longev. 2012, 624925.
194. Venugopal, A., Chaerkady, R., Pandey, A., 2009. Application of mass spectrometrybased proteomics for biomarker discovery in neurological disorders. Ann. Indian Acad. Neurol. 12, 3-11.
195. Vilarino-Guell, C., Wider, C., Aasly, J.O., White, L.R., Rajput, A., Rajput, A.H., Lynch, T., Krygowska-Wajs, A., Jasinska-Myga, B., Opala, G., Barcikowska, M., Czyzewski, K., Wu, R.M., Uitti, R.J., Wszolek, Z.K., Farrer, M.J., Ross, O.A., 2010. Association of pyridoxal kinase and Parkinson disease. Ann. Neurol. 67, 409-411.
196. Vilas, D., Pont-Sunyer, C., Tolosa, E., 2012. Impulse control disorders in Parkinson's disease. Parkinsonism Relat. Disord. 18 (Suppl. 1), S80-S84.
197. Volkow, N.D., Wang, G.J., Fowler, J.S., Tomasi, D., 2012. Addiction circuitry in the human brain. Annu. Rev. Pharmacol. Toxicol. 52, 321-336.
198. Waragai, M., Sekiyama, K., Sekigawa, A., Takamatsu, Y., Fujita, M., Hashimoto, M., 2010. a-Syn and DJ-1 as potential biological fluid biomarkers for Parkinson's disease. Int. J. Mol. Sci. 11, 4257-4266.
199. Waragai, M., Sekiyama, K., Fujita, M., Tokuda, T., Hashimoto, M., 2013. Biomarkers for the diagnosis and management of Parkinson's disease. Expert Opin. Med. Diagn. 7, 71-83.
200. Weintraub, D., Newberg, A.B., Cary, M.S., Siderowf, A.D., Moberg, P.J., Kleiner- Fisman, G., Duda, J.E., Stern, M.B., Mozley, D., Katz, I.R., 2005. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J. Nucl. Med. 46, 227-232. (Pubitemid 43073428)
201. Weintraub, D., Koester, J., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., et al., 2010. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67, 589-595.
202. Wurtman, R.J., 2013. Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits. Metabolism 62, S27-S29.
203. Xie, H., Chang, M., Hu, X., Wang, D., Tian, M., Li, G., Jiang, H., Wang, Y., Dong, Z., Zhang, Y., Hu, L., 2011. Proteomics analysis of MPP+-induced apoptosis in SHSY5Y cells. J. Neurol. Sci. 32, 221-228.
204. Yasuda, T., Nakata, Y., Mochizuki, H., 2013. a-Syn and neuronal cell death. Mol. Neurobiol. 47, 466-483.
205. Zhang, J.L., Yang, J.F., Chan, P., 2009. No association between polymorphism of serotonin transporter gene and depression in Parkinson's disease in Chinese. Neurosci. Lett. 455, 155-158.
206. Zhao, X., Xiao, W.Z., Pu, X.P., Zhong, L.J., 2010. Proteome analysis of the sera from Chinese Parkinson's disease patients. Neurosci. Lett. 479, 175-179.
207. Ziegler, D.A., Wonderlick, J.S., Ashourian, P., Hansen, L.A., Young, J.C., Murphy, A.J., Koppuzha, C.K., Growdon, J.H., 2013. Substantia nigra volume loss before Basal forebrain degeneration in early Parkinson disease. JAMA Neurol. 70, 241-247.